Corona Remedies (CORONA)
Fast GrowerFairStock Score: 25/100 — RISKY
Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹2,137.1 |
| Market Cap | ₹9,707.33 Cr |
| P/E Ratio | 65.8 |
| ROCE | 31.47% |
| ROE | —% |
| Dividend Yield | 0.47% |
| Profit Growth | 30.2% |
| Debt/Equity | 0.22 |
| Sales Growth | 21.9% |
| Promoter Holding | 69% |
| 52-Week Range | ₹1,336.6 — ₹2,261.4 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹122.12 |
Strengths
- ROCE of 31.47% indicates highly efficient use of capital
- Debt/Equity of 0.10 gives strong financial stability
- Sales growth of 15.03% and profit growth of 21.58% show compounding momentum
- Promoter holding of 69% aligns management with minority shareholders
- Piotroski F-Score of 7/9 suggests sound fundamentals
Concerns
- P/E of 60.96 and P/B of 15.22 leave no margin of safety
- PEG of 3.33 implies the stock is expensive relative to its growth rate
- Zero dividend yield means all returns depend on future price appreciation
- FairStock Score of 23/100 flags significant risk
AI Analysis
At ₹1,640.75, Corona Remedies is being priced as if the next decade holds certainty. Sales grew 15.03%, profit grew 21.58%, and ROCE is a handsome 31.47%. Debt is negligible at 0.10 times equity. The Piotroski score of 7/9 also suggests decent financial health. As Graham would say, price is what you pay, value is what you get—and at a P/E of 60.96 and P/B of 15.22, I am paying a fortune. The PEG ratio of 3.33 tells me the earnings growth is already discounted, and then some. With a book value of only ₹107.80, I am buying ₹100 of net assets for ₹1,640. That price must be justified by decades of high return on capital and consistent compounding. The company does earn an impressive ROCE, and promoter holding at 69% is reassuring. But I see no dividend, so my only return comes from future price appreciation, which depends on earnings meeting very optimistic expectations. Profit growth at 21.58% is good, but not extraordinary enough for a 61-times multiple. A FairStock score of 23/100 is a red flag. I need a wide margin of safety to invest here; at this price, I do not have one. I would rather wait for a lower price or a longer track record of execution at this scale. This is a fast grower, but fast growth is not safe growth when you pay a premium for it.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer